Armata Pharmaceuticals, Inc. ARMP
Biotechnology: Biological Products (No Diagnostic Substances) · data as of November 13, 2026
Armata Pharmaceuticals, Inc. (ARMP) is a healthcare company listed in the US with a market value of about $144M.
Its overall Stock Analiz score is 0.2 out of 5 (weak). The strongest part is track record (1/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -78%.
About Armata Pharmaceuticals
Armata Pharmaceuticals is listed in the US and classified in biotechnology: biological products (no diagnostic substances). It was profitable in 0 of the last 10 years in our data. Its share count rose by 6% over three years (dilution for shareholders).
Score: 0.2 / 5
Checks passed
- ROE above 15%
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | — |
| Net income | -$174M | -$19M | -$69M | -$37M | -$23M | -$22M | -$19M | -$17M | -$13M | -$19M |
| Free cash flow | -$26M | -$39M | -$56M | -$35M | -$25M | -$19M | -$16M | -$12M | -$9M | -$11M |
| EPS (diluted) | $-4.80 | $-0.89 | $-1.91 | $-1.08 | $-0.96 | $-1.35 | $-2.55 | $-3.59 | $-8.93 | $-101.06 |
| Net margin | — | — | — | — | — | — | — | — | — | — |
| ROIC | — | -197.2% | -50.0% | -34.4% | -29.7% | -54.5% | -89.4% | -225.0% | -60.3% | -215.7% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 2 analysts is $17.50, 352% above the current price; targets range from $15.00 to $20.00; the consensus rating is “Strong buy”; expected EPS is $-1.46 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Armata Pharmaceuticals pay a dividend?
Not currently.
Is Armata Pharmaceuticals a good stock to buy?
We do not give buy or sell advice. Armata Pharmaceuticals scores 0.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.